Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Abalos Therapeutics GmbH

Headquarters: Dusseldorf, Germany
Year Founded: 2019
Status: Private

BioCentury | Oct 11, 2024
Management Tracks

Flagship takes on a third managing partner

Plus: New CEOs at Wheeler, Abalos, Oncovita, Syneos and Calluna, and updates from Phase, Ziphius and more
BioCentury | Oct 19, 2022
Management Tracks

New chairs at SomaLogic, Anjarium

Plus Dechamps becomes CEO at Bioxodes, and updates from Abalos, M2Gen and Orion
BioCentury | Nov 16, 2021
Data Byte

The oncolytic virus pipeline

At least 49 oncolytic virus therapies now in development behind the sole FDA-approved product
BioCentury | Oct 14, 2021
Finance

Abalos adds €32.5M to series A round

Funds enable German biotech to push immuno-virotherapy into clinic within next two years
BioCentury | Oct 15, 2019
Emerging Company Profile

Abalos’ arena: planning to upstage oncolytic viruses

Abalos launches with €12 million series A to advance its arenavirus-based cancer therapies
Items per page:
1 - 6 of 6